Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children

International Journal of Infectious Diseases

Volumn 12, Issue 6, 2008, Pages

  Lapphra, Keswadee ^a   Vanprapar, Nirun ^a   Chearskul, Sanay ^a   Phongsamart, Wanatpreeya ^a   Chearskul, Pimpanada ^a   Prasitsuebsai, Wasana ^a   Chokephaibulkit, Kulkanya ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Children; Efavirenz; Efficacy; HIV; Nevirapine; Tolerability

Indexed keywords

ANTIHISTAMINIC AGENT; EFAVIRENZ; GPO VIR; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; NEVIRAPINE; PREDNISOLONE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; BEDTIME DOSAGE; CD4 LYMPHOCYTE COUNT; CD4 LYMPHOCYTE PERCENTAGE; CHILD; CONTROLLED STUDY; DEPRESSION; DROWSINESS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHORIA; FEMALE; FEVER; FOLLOW UP; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INFANT; INSOMNIA; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NIGHTMARE; PERIPHERAL LIPOATROPHY; RASH; RECOMMENDED DRUG DOSE; SLEEP DISORDER; STEVENS JOHNSON SYNDROME; SURVIVAL RATE; SURVIVAL TIME; THAILAND; TREATMENT OUTCOME; VIVID DREAM; VOMITING;

ADOLESCENT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; INFANT; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; THAILAND; TREATMENT OUTCOME;

EID: 54349087332     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2007.10.008     Document Type: Article

References (25)

1. Montaner J.S., Reiss P., Cooper D., Vella S., Harris M., Conway B., et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. The INCAS Trial. JAMA 279 (1998) 930-937
2. Cozzi-Lepri A., Phillips A.N., d'Arminio Monforte A., Piersantelli N., Orani A., Petrosillo N., et al. Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naïve Antiretrovirals study. J Infect Dis 185 (2002) 1062-1069
3. Keiser P., Nasser N., White C., Koen G., and Moreno S. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study. HIV Clin Trials 3 (2002) 296-303
4. Matthews G.V., Sabin C.A., Mandalia S., Lampe F., Phillips A.N., Nelson M.R., et al. Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naïve patients: a cohort study. AIDS 16 (2002) 53-61
5. van Leth F., Phanuphak P., Ruxrungtham K., Baraldi E., Miller S., Gazzard B., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomized open-label trial, the 2NN Study. Lancet 363 (2004) 1253-1263
6. The Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection; December 14, 2001. Available at: http://aidsinfo.nih.gov/Contentfiles/PediatricGuidelines12142001021.pdf. (accessed November 2007).
7. Centers for Disease Control Prevention. Guidelines for the use of antiretroviral agents in pediatric HIV infection. MMWR Recomm Rep 47 RR-4 (1998) 1-43
8. Centers for Disease Control Prevention. Revised classification system for human immunodeficiency virus infection in children less than 13 years of ages. MMWR Recomm Rep 43 RR-12 (1994) 1-10
9. Staszewski S., Morales-Ramirez J., Tashima K.T., Rachlis A., Skiest D., Stanford J., et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults: Study 006 Team. N Engl J Med 341 (1999) 1865-1873
10. Podzamczer D., Ferrer E., Consiglio E., Gatell J.M., Perez P., Perez J.L., et al. A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naïve patients (the Combine Study). Antivir Ther 7 (2002) 81-90
11. Van Leeuwen R., Katlama C., Murphy R.L., Squires K., Gatell J., Horban A., et al. A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1 infected patients. AIDS 17 (2003) 987-999
12. Manosuthi W., Sungkanuparph S., Vibhagool A., Rattanasiri S., and Thakkinstian A. Nevirapine- versus efavirenz-based highly active antiretroviral therapy regimens in antiretroviral-naïve patients with advanced HIV-infection. HIV Med 5 (2004) 105-109
13. Puthanakit T., Oberdorfer A., Akarathum N., Kanjanavanit S., Wannarit P., Sirisanthana T., et al. Efficacy of highly active antiretroviral therapy in HIV-infected children participating in Thailand's National Access to Antiretrovirals Program. Clin Infect Dis 41 (2005) 100-107
14. Puthanakit T., Aurpibul L., Oberdorfer P., Akarathum N., Kanjanavanit S., Wannarit P., et al. Sustained immunologic and virologic efficacy after four years of highly active antiretroviral therapy in human immunodeficiency virus infected children in Thailand. Pediatr Infect Dis J 26 (2007) 953-956
15. van Leth F., Andrews S., Grinsztein B., Wilkins E., Lazanas M.K., Lange J.M., et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS 19 (2005) 463-471
16. Fatkenheuer G., Theisen A., Rockstroh J., Grabow T., Wicke C., Becker K., et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 11 (1997) 113-116
17. Mocroft A., Gill M.J., Davidson W., and Phillips A.N. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 12 (1998) 2161-2167
18. Le Moing V., Chene G., Carrieri M.P., Alioum A., Brun-Vezinet F., Piroth L., et al. Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 16 (2002) 21-29
19. Nadal D., Steiner F., Cheseaux J.J., Lazarevitch C.A., Aebi C., Kind C., et al. Long-term responses to treatment including ritonavir or nelfinavir in HIV-1-infected children. Pediatric AIDS Group of Switzerland. Infection 28 (2000) 287-296
20. Resino S., M. Bellon J., Gurbindo D., Tomas Ramos J., Antonio Leon J., Jose Mellado M., et al. Viral load and CD4+ T lymphocyte response to highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children: an observational study. Clin Infect Dis 37 (2003) 1216-1225
21. Starr S.E., Fletcher C.V., Spector S.A., Young F.H., Fenton T., Brundage R.C., et al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N Engl J Med 341 (1999) 1874-1881
22. Lolekha R., Sirivichayakul S., Siangphoe U., Pancharoen C., Kaewchana S., Apateerapong W., et al. Resistance to dual nucleoside reverse-transcriptase inhibitors in children infected with HIV clade A/E. Clin Infect Dis 40 (2005) 309-312
23. Pollard R.B., Robinson P., and Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther 20 (1998) 1071-1092
24. Verweel G., Sharland M., Lyall H., Novelli V., Gibb D.M., Dumont G., et al. Nevirapine use in HIV-1-infected children. AIDS 17 (2003) 1639-1647
25. Teglas J.P., Quartier P., Treluyer J.M., Burgard M., Gregoire V., and Blanche S. Tolerance of efavirenz in children. AIDS 15 (2001) 241-243